Literature DB >> 18423879

Prevention and treatment of type 2 diabetes: current role of lifestyle, natural product, and pharmacological interventions.

Nicholas P Hays1, Pietro R Galassetti, Robert H Coker.   

Abstract

Common complications of type 2 diabetes (T2D) are eye, kidney and nerve diseases, as well as an increased risk for the development of cardiovascular disease and cancer. The overwhelming influence of these conditions contributes to a decreased quality of life and life span, as well as significant economic consequences. Although obesity once served as a surrogate marker for the risk of T2D, we know now that excess adipose tissue secretes inflammatory cytokines that left unchecked, accelerate the progression to insulin resistance and T2D. In addition, excess alcohol consumption may also increase the risk of T2D. From a therapeutic standpoint, lifestyle interventions such as dietary modification and/or exercise training have been shown to improve glucose homeostasis but may not normalize the disease process unless weight loss is achieved and increased physical activity patterns are established. Furthermore, utilization of natural products may serve as a significant adjunct in the fight against insulin resistance but further research is needed to ascertain their validity. Since it is clear that pharmaceutical therapy plays a significant role in the treatment of insulin resistance, this review will also discuss some of the newly developed pharmaceutical therapies that may work in conjunction with lifestyle interventions, and lessen the burden of behavioral change as the only strategy against the development of T2D.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18423879      PMCID: PMC2441900          DOI: 10.1016/j.pharmthera.2008.02.003

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  170 in total

Review 1.  Banting Lecture 1997. Control of glucose uptake and release by the liver in vivo.

Authors:  A D Cherrington
Journal:  Diabetes       Date:  1999-05       Impact factor: 9.461

2.  Exercise-induced changes in insulin action and glycogen metabolism in elderly adults.

Authors:  Robert H Coker; Nicholas P Hays; Rick H Williams; Amy D Brown; Scott A Freeling; Patrick M Kortebein; Dennis H Sullivan; Raymond D Starling; William J Evans
Journal:  Med Sci Sports Exerc       Date:  2006-03       Impact factor: 5.411

Review 3.  The role of impaired early insulin secretion in the pathogenesis of Type II diabetes mellitus.

Authors:  R E Pratley; C Weyer
Journal:  Diabetologia       Date:  2001-08       Impact factor: 10.122

4.  Oral administration of RAC-alpha-lipoic acid modulates insulin sensitivity in patients with type-2 diabetes mellitus: a placebo-controlled pilot trial.

Authors:  S Jacob; P Ruus; R Hermann; H J Tritschler; E Maerker; W Renn; H J Augustin; G J Dietze; K Rett
Journal:  Free Radic Biol Med       Date:  1999-08       Impact factor: 7.376

5.  Enhanced adiponectin multimer ratio and skeletal muscle adiponectin receptor expression following exercise training and diet in older insulin-resistant adults.

Authors:  Valerie B O'Leary; Ashley E Jorett; Christine M Marchetti; Frank Gonzalez; Susan A Phillips; Theodore P Ciaraldi; John P Kirwan
Journal:  Am J Physiol Endocrinol Metab       Date:  2007-05-08       Impact factor: 4.310

6.  Inverse association between fish intake and risk of glucose intolerance in normoglycemic elderly men and women.

Authors:  E J Feskens; C H Bowles; D Kromhout
Journal:  Diabetes Care       Date:  1991-11       Impact factor: 19.112

7.  Interactions of exercise training and alpha-lipoic acid on insulin signaling in skeletal muscle of obese Zucker rats.

Authors:  Vitoon Saengsirisuwan; Felipe R Perez; Julie A Sloniger; Thomas Maier; Erik J Henriksen
Journal:  Am J Physiol Endocrinol Metab       Date:  2004-04-06       Impact factor: 4.310

8.  Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression.

Authors:  Philip A Kern; Gina B Di Gregorio; Tong Lu; Negah Rassouli; Gouri Ranganathan
Journal:  Diabetes       Date:  2003-07       Impact factor: 9.461

9.  Moderate alcohol consumption induces sustained cardiac protection by activating PKC-epsilon and Akt.

Authors:  Hui-Zhong Zhou; Joel S Karliner; Mary O Gray
Journal:  Am J Physiol Heart Circ Physiol       Date:  2002-07       Impact factor: 4.733

10.  Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase.

Authors:  T Yamauchi; J Kamon; Y Minokoshi; Y Ito; H Waki; S Uchida; S Yamashita; M Noda; S Kita; K Ueki; K Eto; Y Akanuma; P Froguel; F Foufelle; P Ferre; D Carling; S Kimura; R Nagai; B B Kahn; T Kadowaki
Journal:  Nat Med       Date:  2002-10-07       Impact factor: 53.440

View more
  26 in total

1.  Injectable protease-operated depots of glucagon-like peptide-1 provide extended and tunable glucose control.

Authors:  Miriam Amiram; Kelli M Luginbuhl; Xinghai Li; Mark N Feinglos; Ashutosh Chilkoti
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-28       Impact factor: 11.205

Review 2.  The globalization of traditional medicine in northern peru: from shamanism to molecules.

Authors:  Rainer W Bussmann
Journal:  Evid Based Complement Alternat Med       Date:  2013-12-28       Impact factor: 2.629

3.  Effect of fish and krill oil supplementation on glucose tolerance in rabbits with experimentally induced obesity.

Authors:  Zhenya Ivanova; Bodil Bjørndal; Natalia Grigorova; Anton Roussenov; Ekaterina Vachkova; Kjetil Berge; Lena Burri; Rolf Berge; Spaska Stanilova; Anelia Milanova; Georgi Penchev; Rita Vik; Vladimir Petrov; Teodora Mircheva Georgieva; Boycho Bivolraski; Ivan Penchev Georgiev
Journal:  Eur J Nutr       Date:  2014-10-15       Impact factor: 5.614

4.  Association of passive and active smoking with incident type 2 diabetes mellitus in the elderly population: the KORA S4/F4 cohort study.

Authors:  Bernd Kowall; Wolfgang Rathmann; Klaus Strassburger; Margit Heier; Rolf Holle; Barbara Thorand; Guido Giani; Annette Peters; Christine Meisinger
Journal:  Eur J Epidemiol       Date:  2010-04-06       Impact factor: 8.082

5.  MEK/ERK pathway activation by insulin receptor isoform alteration is associated with the abnormal proliferation and differentiation of intestinal epithelial cells in diabetic mice.

Authors:  Hui Ouyang; Hong-Sheng Yang; Tao Yu; Ti-Dong Shan; Jie-Yao Li; Can-Ze Huang; Wa Zhong; Zhong-Sheng Xia; Qi-Kui Chen
Journal:  Mol Cell Biochem       Date:  2016-01-02       Impact factor: 3.396

6.  miRNA-30e regulates abnormal differentiation of small intestinal epithelial cells in diabetic mice by downregulating Dll4 expression.

Authors:  Ti-Dong Shan; Hui Ouyang; Tao Yu; Jie-Yao Li; Can-Ze Huang; Hong-Sheng Yang; Wa Zhong; Zhong-Sheng Xia; Qi-Kui Chen
Journal:  Cell Prolif       Date:  2016-01-19       Impact factor: 6.831

7.  High-fat feeding and Staphylococcus intermedius infection impair beta cell function and insulin sensitivity in mongrel dogs.

Authors:  Evgeni Slavov; Ivan Penchev Georgiev; Petko Dzhelebov; Ivan Kanelov; Maria Andonova; Teodora Mircheva Georgieva; Silviya Dimitrova
Journal:  Vet Res Commun       Date:  2010-03-02       Impact factor: 2.459

8.  A spectrum of contributions of type 2 diabetes and related metabolic characteristics to dementia.

Authors:  Ramit Ravona-Springer; Michal Schnaider Beeri
Journal:  Eur Neuropsychopharmacol       Date:  2014-12       Impact factor: 4.600

9.  A depot-forming glucagon-like peptide-1 fusion protein reduces blood glucose for five days with a single injection.

Authors:  M Amiram; K M Luginbuhl; X Li; M N Feinglos; A Chilkoti
Journal:  J Control Release       Date:  2013-08-06       Impact factor: 9.776

10.  The impact of exercise training compared to caloric restriction on hepatic and peripheral insulin resistance in obesity.

Authors:  Robert H Coker; Rick H Williams; Sophie E Yeo; Patrick M Kortebein; Don L Bodenner; Philip A Kern; William J Evans
Journal:  J Clin Endocrinol Metab       Date:  2009-10-06       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.